The global sales of infertility treatment are estimated to be worth USD 1,899.8 million in 2024 and are anticipated to reach a value of USD 3,843.3 million by 2034. Sales are projected to rise at a CAGR of 7.3% over the forecast period between 2024 and 2034. The revenue generated by infertility treatment in 2023 was USD 1,770.6 million. The industry is anticipated to exhibit a Y-o-Y growth of 7.4% in 2024.
Infertility affects both partners in different ways due to a myriad of conditions. Diagnosing and treating infertility involves a range of specialized devices and instruments. The treatment is highly individualized, depending on the etiology of the infertility, and may take the lines of surgery or medication, or ART.
Changing lifestyles, late marriages, and environmental factors have resulted in an increasing number of infertility cases, thereby driving the demand for infertility treatments. Moreover, infertility as a side effect of medical conditions such as PCOS and other reproductive disorders also fuels the market growth for such treatments.
Global Infertility Treatment Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 1,770.6 million |
| Estimated Size, 2024 | USD 1,899.8 million |
| Projected Size, 2034 | USD 3,843.3 million |
| Value-based CAGR (2024 to 2034) | 7.3% |
A lot of people decide to postpone pregnancy when they wish to settle in the career before having children. With age, a woman's fertility decreases, and hence conceiving gets harder. The increased awareness of problems relating to infertility has made several couples seek medical help.
This consists of a variety of treatments that acquire cures from medicines and surgeries to those of assisted reproductive technology, i.e., In vitro fertilization. With increasing knowledge on infertility, more and more people are approaching to seek these treatments to counter their CD problem.
As the understanding regarding infertility issues improves, more people get aware about infertility issues, and therefore more people opt for professional help. It is now easier for people to discuss and address openly their fertility concerns because of the reduced stigma associated with reproductive technologies through media coverage, educational initiatives, and advocacy.
This change in perception has led to increased acceptance of better treatment options like IVF, IUI, and egg or sperm donation; hence more patients are now coming forward to seek these services. This increased awareness has expanded the industry’s growth.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The table below compares the compound annual growth rate (CAGR) for the global infertility treatment industry from 2023 to 2024 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into industry dynamics.
H1 covers January to June, while H2 spans July to December. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 8.4%, followed by a slightly lower growth rate of 8.0% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 8.4% (2023 to 2033) |
| H2 | 8.0% (2023 to 2033) |
| H1 | 7.3% (2024 to 2034) |
| H2 | 6.9% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 7.3% in the first half and remain relatively moderate at 6.9% in the second half. In the first half (H1) the industry witnessed a decrease of 110 BPS while in the second half (H2), the industry witnessed a decrease of 110 BPS.
Rise in infertility cases due to disorders such as PCOS driving the market growth
PCOS is the most common factor for hormonal disorders in childbearing women, resulting in infertility due to irregular menstrual cycle and obesity, by raising excessive androgen levels in the body. As the incidence of PCOS increases in women, healthcare professionals are promoted to work on medicines and assisted reproductive techniques to cure infertility caused by PCOS.
Increased awareness about PCOS goes hand in hand with demands to treat it more efficiently so that women can manage their symptoms and boost their fertility potential. The rising health awareness among females is creating a social trend wherein they are seeking help for their reproductive problems and hence demand for infertility treatment.
As healthcare systems evolve to simply meet this ever-increasing demand, new opportunities in the marketplace for PCOS-related infertility treatments will also increase for patients and health providers alike, looking to achieve improved reproductive health outcomes.
For instance, according to an article published in Cureus, an open-access medical journal, in August 2022, there are around 116 million women currently suffering from PCOS globally.
Thus, increasing prevalence of PCOS would eventually lead to rise in infertility. This is expected to increase the demand for proper treatment for infertility among women, which drives the market growth.
Technological advancements in infertility treatment creates a window of opportunity
Technological advancements have significantly improved the success rate of treatments and increased the number of patients seeking treatment. Improved imaging systems and time-lapse technologies changed the face of fertility treatment administration.
Time-lapse imaging, for instance, enhances the ability to monitor embryo development continuously without removing it from the incubator, which enables embryologists to select the most viable embryos based on their growth pattern. This kind of accuracy in the selection of the embryo would also increase the chances of proper implantation and pregnancy.
Genetic diagnosis was the next step forward, where Preimplantation Genetic Testing made even the identification of genetic abnormalities in embryos possible before implantation and reduced the incidence of hereditary disorders, therefore improving success rates overall.
Artificial intelligence dramatically affects fertility treatment because it makes a deep analysis of large reams of data to provide individual treatment recommendations that help in optimizing protocols for better outcomes. Second, improvements in cryopreservation techniques have very much helped to preserve embryos and ovarian tissue, hence giving patients a chance to plan the treatments better.
In the future also, these technologies will continue to evolve, improving the effectiveness of treatments for infertility and empowering individuals and couples to seek assistance on their journey to parenthood.
Shift toward personalized infertility treatments is a major trend in this market
Tailoring the approaches to the needs of different patients makes it more effective and raises patient satisfaction since it acknowledges that infertility can result from age, lifestyle, and underlying diseases. Advanced diagnostics, with genetic testing and biomarker screenings at their head, help design targeted treatment plans that suit the specific causes of infertility in a given patient.
Targeted therapies may involve tailored doses of medication, the best selection of appropriate assisted reproductive technology, or the best timing of procedures based on a patient's individualized biological markers. For instance, the use of endometrial receptivity arrays can help identify the ideal window for embryo implantation, increasing the chances of a successful pregnancy.
As understanding of infertility deepens, further support for personalized care is created with the integration of technologies such as artificial intelligence, which further supports personalized care by analysis of patient data to optimize treatment protocols. The trend enhances clinical outcomes and the feeling of empowerment by the patient with involvement in the treatment journey.
High cost of infertility treatment devices may Restrict Infertility Treatment Market Growth
High treatment costs using assisted reproductive technologies (ART) are a major restraint to market growth. Procedures under ART, such as in vitro fertilization, also known as IVF, may run into a significant amount for a couple, up to USD 15,000 to USD 30,000 per cycle in the USA These high costs can limit access to treatment and lead to financial hardship for those seeking to conceive.
Most of the advanced devices and procedures in infertility assistances are very expensive; hence, a good number of populations cannot access these services. This makes a section of the population shun away from seeking treatment due to the high costs involved, or they may lead to strained finances for those who may seek services.
The high costs of ART are also attributed to the complexity of the procedures involved, the specialization of the equipment and facilities, as well as the vast team of health professionals involved.
In this respect, ART is not covered by insurance or state-run programs for many countries, leaving the entire burden to patient’s pockets and, therefore, out of reach for many. This could mean that fewer numbers can afford the necessary treatment, hence a retardation of the market generally speaking.
Principal Consultant
The global infertility treatment industry recorded a CAGR of 6.6% during the historical period between 2019 and 2023. The growth of infertility treatment industry was positive as it reached a value of USD 3,843.3 million in 2034 from USD 1,899.8 million in 2024.
Historically, there has been a stigma associated with the treatment of infertility that has led to a great amount of social isolation for many individuals. In years gone by, most cultures looked at infertility as a personal failure, mainly laying blame on the woman, hence keeping her from coming forward to seek medical assistance.
Such lack of awareness about infertility as a medical condition rendered access to effective treatments difficult, hence sustaining myths and misconceptions. For example, development in medical science over time has begun to break such cultural perceptions by providing more understanding about infertility and its treatment.
Several factors contribute to growing the infertility treatment market. First, the decline in fertility rates worldwide, mostly due to late marriages and age-related infertility cases, increases the demand for treatment methods. With the trend of couples delaying starting families for personal or professional reasons, the need for assisted reproductive technologies increased many-fold.
Another reason contributing to this increase is the rising cases of infertility conditions, such as PCOS and hormonal disorders that compel more people to seek medical help.
Better infertility treatment options, novel procedures, and better imaging systems have contributed to greater success rates in treatment, thus attracting more patients. Another reason for the growth is increased access to such services, corresponding to the opening of fertility clinics all over the world.
Furthermore, growing awareness and acceptance among people with regard to infertility treatments for same-sex couples and single parents are also on the rise, thereby increasing market size. All these factors are fueling rapid growth in the infertility treatment market, suggestive of a trend toward more comprehensive reproductive health solutions.
Tier 1 companies are the industry leaders as they hold a substantial 28.5% value share worldwide. These companies have generated revenue over USD 100 million. These companies have large product portfolio and a high production capacity. These industry leaders stand out for having a wide geographic reach, and a strong customer base.
They offer a variety of products. Prominent companies within tier 1 include Thermo Fisher Scientific, Cook Group, and CooperSurgical Inc.
Mid-size businesses with annual revenue between USD 50 and USD 100 million and which are capturing a value share of 36.5% in global market, and that are based in particular areas and have a significant impact on the local industry are considered Tier 2 companies. These companies have regional presence and in-depth industry expertise.
These companies also have large product portfolio. However, less as compared with tier 1 players. Prominent companies in tier 2 include AB Scientific Ltd., Vitrolife, IVFtech APS and Hamilton Thorne Ltd.
Tier 3 companies, although, smaller but are essential for the growth of the industry. Compared with tier 1 and tier 2 these companies have limited product portfolio and has lesser revenue. These companies cater to one or two countries. The companies such as Esco Micro Pte Ltd., Genea Biomedx Ltd., FUJIFILM Irvine Scientific, Baker Company INC. and other falls under this category.
They specialize in specific products and cater to niche markets, adding diversity to the industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the infertility treatment market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East & Africa, is provided.
The United States is anticipated to remain at the forefront in North America, with a value share of 81.6% through 2034. In Asia Pacific, China is projected to witness a CAGR of 7.3% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| USA | 2.3% |
| Germany | 2.3% |
| France | 3.7% |
| UK | 2.6% |
| China | 7.3% |
| India | 8.3% |
| South Korea | 5.7% |
Germany’s infertility treatment market is expected to exhibit a CAGR of 2.3% between 2024 and 2034. The Germany holds highest market share in European market.
The growth in the German infertility treatment market has been contributed by government sponsorship of research projects. Federal and state governments have granted priority to fund scientific research in the field of health care and biotech, which usually has a direct application in new infertility treatment developments.
Reproductive health research is generously funded by the government under various funding programs and strategic measures, such as the Excellence Strategy and the Future Strategy for Research and Innovation, among others.
This financing propels collaboration among academia, research organizations, and private enterprise, thus furthering cutting-edge technologies in assisted reproductive techniques. The commitment to research funding for advancing reproductive health ultimately strengthens Germany's strength in innovation and leadership in infertility treatments.
The USA market is anticipated to grow at a CAGR of 2.3% throughout the forecast period.
The growing number of fertility clinics in the USA continues to fuel the market for infertility treatment. The establishment of the facilities throughout the country follows an increased awareness about infertility issues among a large number of individuals and couples, hence creating a demand for specifically concerned treatment services.
A wide range of services is tied to be delivered through these facilities catering to patient needs, including assisted reproductive technologies (ART) like in vitro fertilization (IVF) and intrauterine insemination (IUI).
The growth of fertility clinics increases access to treatments and makes it easier for patients to get in touch for help in case of any need. The rise in developed technology and medical practices through these clinics increases the success rates and makes more and more patients come seeking treatment. The rise in fertility clinics also serves as evidence of the shift in social norms because a greater number of people are signing up for reproductive services.
The China is expected to hold a dominating position in East Asia market of infertility treatment and is anticipated to grow at a CAGR of 7.3% throughout the forecast period.
The country is becoming one of the most preferred destinations in the world for patients in search of high-quality, low-cost fertility treatments. The country possesses leading medical technologies coupled with experienced professionals who seek to target the niche of affordable reproductive technologies among patients like in vitro fertilization technologies.
The government has also backed the medical tourism industry in making healthcare reforms and ensuring that medical zones are set up professionally, thus improving the experience. More awareness of infertility issues all over the world and more acceptance of medical tourism mean that more couples will also consider China for their fertility treatment needs.
This trend expands the market, and China becomes competitive in the global arena of infertility treatment.
The section contains information about the leading segments in the industry. Based on product, the media & consumables is expected to account for 46.6% of the global market share in 2024.
| Product | Media & Consumables |
|---|---|
| Value Share (2024) | 46.6% |
The media & consumables segment is expected to dominate the market in terms of revenue, accounting for almost 46.6% of the market share in 2024. The prime segment to dominate the infertility treatment market is projected to be the media & consumables because, for most consumers, it is easy to obtain and is not too costly.
Moreover, the media and consumable plays a vital role during treatment procedures. Consumables, like hormones and diagnostic kits, are used frequently and require continuous replenishment, driving significant recurring revenue.
Increasing usage of different types of media to culture embryos coupled with the expansion of IVF devices and the consumables market will further boost the growth of this segment. In addition, whenever the in-vitro fertilization is performed there is a need for media & consumables. Moreover, in every facility media & consumables will be consumed more and will generate recurring revenue.
| Procedure | Assisted Reproductive Technology |
|---|---|
| Value Share (2024) | 31.7% |
By procedure, the assisted reproductive technology segment is projected to hold a major market share of 31.7% in 2024.
ART dominates the infertility treatment market for varied reasons. The success rates of such procedures have increased manifold with advances in techniques, especially the method of in vitro fertilization. More adoption and acceptability of ART as an effective means of achieving pregnancy in cases of infertility further add to its dominance.
There is also more significant institutional financial backing and more insurance coverage in many countries towards ART treatments, thus making these services accessible to many people.
The number of fertility clinics and hospitals with advanced ART services has also been growing in both developed and developing areas. All these factors make ART the largest procedure segment of the infertility treatment market, and it is likely to continue in the future.
The infertility treatment market is highly fragmented. There are large number infertility treatment manufacturer in the global market involved in developing innovative products so that they can meet their customer’s needs.
Prominent manufacturer of infertility treatment products are focused on growing internationally in order to increase their revenue and increase the size of their sales footprint in developing nations through the purchase of regional competitors. Manufacturers utilize various key strategies such as agreements, product launches, research sponsorship, and strategic collaborations to boost product sales and establish their market presence.
Some of the major player in Infertility Treatment Market includes
In terms of product, the industry is divided into equipment (microscopes, imaging systems, sperm analyser systems, ovum aspiration pumps, micromanipulator systems, incubators, gas analyzers, laser systems, cryosystems, and sperm separation devices), media & consumables and accessories
In terms of procedure, the industry is divided into assisted reproductive technology [in vitro fertilization (intracytoplasmic morphologically selected sperm injection and gamete donation), intracytoplasmic sperm injection, and surrogacy], artificial insemination (intrauterine insemination, intracervical insemination and intratubal insemination), fertility surgeries [laparoscopy, hysteroscopy, varicocelectomy, laparotomy, tubal ligation reversal, microsurgical reconstruction (vasovasostomy and vasoepididymostomy)] and other infertility treatment procedures
In terms of patient type, the industry is segregated into female infertility treatment and male infertility treatment.
In terms of end user, the industry is segregated into fertility centers, hospitals & surgical clinics, cryobanks, and research institutes
Key countries of North America, Latin America, Europe, East Asia, South Asia & Pacific, Middle East and Africa (MEA) have been covered in the report.
The global infertility treatment industry is projected to witness CAGR of 7.3% between 2024 and 2034.
The global infertility treatment industry stood at USD 1,770.6 million in 2023.
The global infertility treatment industry is anticipated to reach USD 3,843.3 million by 2034 end.
China is expected to show a CAGR of 7.3% in the assessment period.
The key players operating in the global infertility treatment industry include Thermo Fisher Scientific, Cook Group, CooperSurgical Inc., Vitrolife, IVFtech APS, Hamilton Thorne Ltd., Esco Micro Pte Ltd., Genea Biomedx Ltd., FUJIFILM Irvine Scientific and Baker Company INC.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis, 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis, and Future Projections 5. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034 5.1. By Product 5.2. By Procedure 5.3. By Patient Type 5.4. By End User 5.5. By Region 6. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Product 6.1. Equipment 6.2. Media & Consumables 6.3. Accessories 7. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Procedure 7.1. Assisted Reproductive Technology 7.2. Artificial Insemination 7.3. Fertility Surgeries 7.4. Other Infertility Treatment Procedures 8. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Patient Type 8.1. Female Infertility Treatment 8.2. Male Infertility Treatment 9. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by End User 9.1. Fertility Centres 9.2. Hospitals & Surgical Clinics 9.3. Cryobanks 9.4. Research Institutes 10. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Region 10.1. North America 10.2. Latin America 10.3. East Asia 10.4. South Asia and Pacific 10.5. Western Europe 10.6. Eastern Europe 10.7. Middle East and Africa 11. North America Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. East Asia Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. South Asia & Pacific Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Western Europe Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Eastern Europe Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East and Africa Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Product, Procedure, Patient Type and End User for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis, by Key Players, and Competition Dashboard 20. Company Profile 20.1. Thermo Fisher Scientific 20.2. Cook Group 20.3. CooperSurgical Inc. 20.4. AB Scientific Ltd. 20.5. Vitrolife 20.6. IVFtech APS 20.7. Hamilton Thorne Ltd. 20.8. Esco Micro Pte Ltd. 20.9. Genea Biomedx Ltd. 20.10. FUJIFILM Irvine Scientific 20.11. Baker Company INC.
Explore Healthcare Insights
View Reports
Infertility Treatment Market
